Literature DB >> 15278203

[The significance of comorbidity and age in radical prostatectomy].

M Wirth1, M Fröhner.   

Abstract

The coexistence of another diagnosis beside the index disease under study is defined as comorbidity. Comorbidity increases with advancing age. In candidates for radical prostatectomy, two aspects of comorbidity are of interest: its association with perioperative complications and long-term survival. The Charlson score is the most extensively studied comorbidity classification for the prediction of long-term outcome. Several studies have identified this score as an independent prognostic factor in the prostate cancer setting. In addition to the Charlson score, data collected during the preoperative cardiopulmonary risk assessment may deliver information identifying patients with an increased long-term mortality risk. The meaningfulness of comorbidity in predicting overall mortality seems to be comparable to that of the Gleason score, the most important tumor-related predictor of survival in prostate cancer. The identification of prognostically relevant single conditions and the development of a "radical prostatectomy-specific" comorbidity classification might improve the stratification of candidates for radical prostatectomy in the future.

Entities:  

Mesh:

Year:  2004        PMID: 15278203     DOI: 10.1007/s00120-004-0640-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  28 in total

1.  The American Society of Anesthesiologists' class as a comorbidity index in a cohort of head and neck cancer surgical patients.

Authors:  B C Reid; A J Alberg; A C Klassen; W M Koch; J M Samet
Journal:  Head Neck       Date:  2001-11       Impact factor: 3.147

Review 2.  Radical retropubic prostatectomy. Preoperative management.

Authors:  N Rosenblum; H Lepor
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

Review 3.  Measurement and impact of comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Crit Rev Oncol Hematol       Date:  2000-09       Impact factor: 6.312

Review 4.  How to measure comorbidity. a critical review of available methods.

Authors:  Vincent de Groot; Heleen Beckerman; Gustaaf J Lankhorst; Lex M Bouter
Journal:  J Clin Epidemiol       Date:  2003-03       Impact factor: 6.437

5.  Which conditions contributing to the Charlson score predict survival after radical prostatectomy?

Authors:  Michael Froehner; Rainer Koch; Rainer Litz; Sven Oehlschlaeger; Manfred P Wirth
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

6.  Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis.

Authors:  M J Barry; P C Albertsen; M A Bagshaw; M L Blute; R Cox; R G Middleton; D F Gleason; H Zincke; E J Bergstralh; S J Jacobsen
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

7.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

8.  Relationship of comorbidity, age and perioperative complications in patients undergoing radical prostatectomy.

Authors:  M Froehner; R Litz; A Manseck; O W Hakenberg; S Leike; D M Albrecht; M P Wirth
Journal:  Urol Int       Date:  2001       Impact factor: 2.089

Review 9.  Contemporary results of anatomic radical prostatectomy.

Authors:  W J Catalona; C G Ramos; G F Carvalhal
Journal:  CA Cancer J Clin       Date:  1999 Sep-Oct       Impact factor: 508.702

10.  Hormone therapy for locally advanced prostate cancer.

Authors:  Jackson E Fowler; Steven A Bigler; Paige C White; William L Duncan
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

View more
  2 in total

1.  [New concept minimizes bleeding in radical retropubic prostatectomy].

Authors:  M Schostak; K Matischak; M Schäfer; M Müller; M Schrader; F Christoph; K Miller
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

Review 2.  [Selection criteria for the expected management of localised prostate cancer].

Authors:  M Graefen; G Salomon; E Currlin; C Eichelberg; T Schlomm; H Huland
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.